FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080682404> ?p ?o ?g. }

• W2080682404 endingPage "1913" @default.
• W2080682404 startingPage "1906" @default.
• W2080682404 abstract "ABSTRACT We compared the efficacy and the toxicity of zidovudine (AZT) versus stavudine (d4T), in combination with lamivudine (3TC) and indinavir, in AZT-, dideoxyinosine (ddI)-, and/or dideoxycytosine (ddC)-experienced patients in a randomized comparative multicenter trial. One hundred seventy human immunodeficiency virus type 1 (HIV-1)-infected patients, who had received AZT, ddI, and/or ddC for at least 6 months but were naive for d4T, 3TC, and protease inhibitors, were randomized to AZT at 250 to 300 mg twice daily, 3TC at 150 mg twice daily, and indinavir at 800 mg every 8 h or to d4T at 40 mg twice daily, 3TC at 150 mg twice daily, and indinavir at 800 mg every 8 h. The primary endpoint was time to virological failure, defined as plasma HIV-1 RNA levels of >5,000 copies/ml after at least 8 weeks of antiretroviral therapy. Additional endpoints were change from baseline in CD4 cell counts, AIDS-defining events and adverse events, and proportion of patients with HIV-1 RNA levels of <500 copies/ml and HIV-1 RNA levels of <50 copies/ml. At week 80, 15 patients in the AZT arm and 14 patients in the d4T arm had reached the primary endpoint, and time to virological failure did not differ between the two arms ( P = 0.98). In the d4T and in the AZT arms, 67 and 73% of patients, respectively, had HIV-1 RNA levels of <500 copies/ml ( P = 0.50). The median change from baseline in CD4 cell count was 195 × 10 6 and 175 × 10 6 /liter for the d4T- and AZT-containing arms, respectively. The proportions of patients with HIV-1 RNA levels of <50 copies/ml at weeks 8, 16, and 24 were similar in the two arms. The occurrence of serious adverse events was not significantly different between arms. In conclusion, in these patients heavily pretreated with AZT, switching from AZT to d4T when initiating indinavir and 3TC did not bring any additional benefit compared to maintaining AZT." @default.
• W2080682404 created "2016-06-24" @default.
• W2080682404 creator A5000969643 @default.
• W2080682404 creator A5003806508 @default.
• W2080682404 creator A5011828459 @default.
• W2080682404 creator A5012588187 @default.
• W2080682404 creator A5029188174 @default.
• W2080682404 creator A5029948764 @default.
• W2080682404 creator A5033573052 @default.
• W2080682404 creator A5047124634 @default.
• W2080682404 creator A5070469805 @default.
• W2080682404 creator A5071071745 @default.
• W2080682404 creator A5080569287 @default.
• W2080682404 creator A5082925576 @default.
• W2080682404 date "2002-06-01" @default.
• W2080682404 modified "2023-09-29" @default.
• W2080682404 title "Efficacy of Zidovudine Compared to Stavudine, Both in Combination with Lamivudine and Indinavir, in Human Immunodeficiency Virus-Infected Nucleoside-Experienced Patients with No Prior Exposure to Lamivudine, Stavudine, or Protease Inhibitors (Novavir Trial)" @default.
• W2080682404 cites W1971307510 @default.
• W2080682404 cites W1984270093 @default.
• W2080682404 cites W1997844736 @default.
• W2080682404 cites W2005873387 @default.
• W2080682404 cites W2025351576 @default.
• W2080682404 cites W2029152314 @default.
• W2080682404 cites W2035938088 @default.
• W2080682404 cites W2057826571 @default.
• W2080682404 cites W2079201451 @default.
• W2080682404 cites W2099697190 @default.
• W2080682404 cites W2121802915 @default.
• W2080682404 cites W2134817712 @default.
• W2080682404 cites W2142910784 @default.
• W2080682404 cites W2144838726 @default.
• W2080682404 cites W2154439050 @default.
• W2080682404 cites W2165657451 @default.
• W2080682404 cites W2318289184 @default.
• W2080682404 cites W2321068669 @default.
• W2080682404 cites W2321852728 @default.
• W2080682404 cites W2329393410 @default.
• W2080682404 cites W2339219218 @default.
• W2080682404 cites W2398913977 @default.
• W2080682404 doi "https://doi.org/10.1128/aac.46.6.1906-1913.2002" @default.
• W2080682404 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/127263" @default.
• W2080682404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12019107" @default.
• W2080682404 hasPublicationYear "2002" @default.
• W2080682404 type Work @default.
• W2080682404 sameAs 2080682404 @default.
• W2080682404 citedByCount "22" @default.
• W2080682404 countsByYear W20806824042012 @default.
• W2080682404 countsByYear W20806824042017 @default.
• W2080682404 countsByYear W20806824042022 @default.
• W2080682404 crossrefType "journal-article" @default.
• W2080682404 hasAuthorship W2080682404A5000969643 @default.
• W2080682404 hasAuthorship W2080682404A5003806508 @default.
• W2080682404 hasAuthorship W2080682404A5011828459 @default.
• W2080682404 hasAuthorship W2080682404A5012588187 @default.
• W2080682404 hasAuthorship W2080682404A5029188174 @default.
• W2080682404 hasAuthorship W2080682404A5029948764 @default.
• W2080682404 hasAuthorship W2080682404A5033573052 @default.
• W2080682404 hasAuthorship W2080682404A5047124634 @default.
• W2080682404 hasAuthorship W2080682404A5070469805 @default.
• W2080682404 hasAuthorship W2080682404A5071071745 @default.
• W2080682404 hasAuthorship W2080682404A5080569287 @default.
• W2080682404 hasAuthorship W2080682404A5082925576 @default.
• W2080682404 hasBestOaLocation W20806824042 @default.
• W2080682404 hasConcept C126322002 @default.
• W2080682404 hasConcept C159047783 @default.
• W2080682404 hasConcept C168563851 @default.
• W2080682404 hasConcept C203092338 @default.
• W2080682404 hasConcept C2522874641 @default.
• W2080682404 hasConcept C2776452011 @default.
• W2080682404 hasConcept C2777210460 @default.
• W2080682404 hasConcept C2777447569 @default.
• W2080682404 hasConcept C2777869810 @default.
• W2080682404 hasConcept C2779889181 @default.
• W2080682404 hasConcept C2780216070 @default.
• W2080682404 hasConcept C2780593183 @default.
• W2080682404 hasConcept C2780727368 @default.
• W2080682404 hasConcept C71924100 @default.
• W2080682404 hasConcept C86803240 @default.
• W2080682404 hasConcept C90924648 @default.
• W2080682404 hasConcept C98274493 @default.
• W2080682404 hasConceptScore W2080682404C126322002 @default.
• W2080682404 hasConceptScore W2080682404C159047783 @default.
• W2080682404 hasConceptScore W2080682404C168563851 @default.
• W2080682404 hasConceptScore W2080682404C203092338 @default.
• W2080682404 hasConceptScore W2080682404C2522874641 @default.
• W2080682404 hasConceptScore W2080682404C2776452011 @default.
• W2080682404 hasConceptScore W2080682404C2777210460 @default.
• W2080682404 hasConceptScore W2080682404C2777447569 @default.
• W2080682404 hasConceptScore W2080682404C2777869810 @default.
• W2080682404 hasConceptScore W2080682404C2779889181 @default.
• W2080682404 hasConceptScore W2080682404C2780216070 @default.
• W2080682404 hasConceptScore W2080682404C2780593183 @default.
• W2080682404 hasConceptScore W2080682404C2780727368 @default.
• W2080682404 hasConceptScore W2080682404C71924100 @default.
• W2080682404 hasConceptScore W2080682404C86803240 @default.
• W2080682404 hasConceptScore W2080682404C90924648 @default.
• W2080682404 hasConceptScore W2080682404C98274493 @default.
• W2080682404 hasIssue "6" @default.

• next